Ontology highlight
ABSTRACT:
PROVIDER: EGAO00000000408 | EGA |
REPOSITORIES: EGA
Annals of oncology : official journal of the European Society for Medical Oncology 20150223 6
<h4>Background</h4>Chronic myeloid leukaemia (CML) is characterised by the presence of a fusion driver oncogene, BCR-ABL1, which is a constitutive tyrosine kinase. Tyrosine kinase inhibitors (TKIs) are the central treatment strategy for CML patients and have significantly improved survival rates, but the T315I mutation in the kinase domain of BCR-ABL1 confers resistance to all clinically approved TKIs, except ponatinib. However, compound mutations can mediate resistance even to ponatinib and rem ...[more]